Affiliation:
1. Russian Society of Oncomammologists
2. Russian Society of Oncomammologists; N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
Abstract
Many patients with different malignancies require analgesic therapy not only at advanced stages of the disease, but also during their diagnosis and treatment, as well as after treatment completion to ensure pain relief. New highly effective painkillers with a lower adverse event burden are critical to improve the quality of life of cancer patients with chronic pain syndrome. Tafalgin (tyrosyl-arginyl-phenylalanyl-glycinamide) is a highly specific μ1-opioid receptor agonist. It is an innovative Russian drug for subcutaneous administration, which has no analogues abroad. This article discusses the results of phase I–III clinical trials assessing tafalgin efficacy, safety, and potential to improve patients’ quality of life.
Publisher
Publishing House ABV Press
Subject
Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference12 articles.
1. Caraceni A., Shkodra M. Cancer pain assessment and classification. Cancers (Basel) 2019; 11 (4): 510. DOI: 10.3390/cancers11040510
2. International Association for the Study of Pain (IASP); 1992. Available at: http://www.iasp-pain.org.
3. World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization, 2018.
4. Paice J. A., Bell R. F., Kalso E. A., Soyyannwo O. A. Cancer Pain: From Molecules to Suffering. IASP Press, 2010.
5. Kosorukov V. S., Abuzarova G. R., Zakharochkina E. R. et al. Tafalgin: an innovative tetrapeptide for subcutaneous administration: a review of the results of phase I and II clinical trials. Opukholi golovy i shei = Head and Neck Tumors 2022; 12 (2): 89–107. (In Russ.)